Merck KGaA Boosted By Bavencio, Mavenclad And COVID Vaccine Fees
Healthy Q3 For 'Big Three'
The German group's efforts in helping its peers in the industry with their respective COVID-19 vaccines have been rewarded with strong revenue growth while its own newer drugs beat analyst forecasts.
You may also be interested in...
Sky-high sales growth of the German major’s Bavencio and Mavenclad caught the eye of some observers as the firm continues to advance these drugs in new disease settings to unlock their full potential.
Merck will develop Chord’s lead drug candidate, an oral version of cladribine, for the treatment of neuromyelitis optica spectrum disorders and generalized myasthenia gravis.
Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.